Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Rene Gonzalez"'
Autor:
Rene Gonzalez, Michele Maio, Piotr Rutkowski, David W. Hogg, R. Dummer, Ivan Marquez-Rodas, John Wagstaff, Jasmine I. Rizzo, Patrick Schöffski, Paolo A. Ascierto, Michael Smylie, A. Balogh, Jedd D. Wolchok, Georgina V. Long, James Larkin, Andriy Moshyk, Vanna Chiarion-Sileni, C. Lebbé, A. Hill, Lars Bastholt, G.A. Daniels, Charles Lance Cowey, Christopher D. Lao, Grant A. McArthur, Massimo Guidoboni, Jean-Jacques Grob, F.S. Hodi, John B A G Haanen, Pier Francesco Ferrucci, Dirk Schadendorf, M.S. Carlino
Publikováno v:
Larkin, J, Chiarion-Sileni, V, Gonzalez, R, Grob, J J, Rutkowski, P, Lao, C D, Cowey, C L, Schadendorf, D, Wagstaff, J, Dummer, R, Ferrucci, P F, Smylie, M, Hogg, D, Hill, A, Márquez-Rodas, I, Haanen, J, Guidoboni, M, Maio, M, Schöffski, P, Carlino, M S, Lebbé, C, McArthur, G, Ascierto, P A, Daniels, G A, Long, G V, Bastholt, L, Rizzo, J I, Balogh, A, Moshyk, A, Hodi, F S & Wolchok, J D 2019, ' Five-year survival with combined nivolumab and ipilimumab in advanced melanoma ', New England Journal of Medicine, vol. 381, no. 16, pp. 1535-1546 . https://doi.org/10.1056/NEJMoa1910836
BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial. METHODS We random
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14214ba6e36377d45b49b748e80793b0
https://cronfa.swan.ac.uk/Record/cronfa52612/Download/52612__16498__4918d35a3c684b7481298e44ab4be851.pdf
https://cronfa.swan.ac.uk/Record/cronfa52612/Download/52612__16498__4918d35a3c684b7481298e44ab4be851.pdf
Autor:
Rafia Bhore, Jonathan Cebon, Oliver Bechter, Dirk Schadendorf, Grant A. McArthur, Jean-Jacques Grob, John Wagstaff, Piotr Rutkowski, Ivan Marquez-Rodas, David Hogg, Jeffrey A. Sosman, Jedd D. Wolchok, Vanna Chiarion-Sileni, Matteo S. Carlino, Linda Rollin, Andrew F. Hill, Pier Francesco Ferrucci, Georgina V. Long, Michael Smylie, James Larkin, Christopher D. Lao, Dana Walker, Massimo Guidoboni, Rene Gonzalez, Margaret K. Callahan, Michael A. Postow, Paolo A. Ascierto, Michele Maio, John B. A. G. Haanen, C. Lance Cowey, Reinhard Dummer, Céleste Lebbé, F. Stephen Hodi
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
BackgroundNivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d35613029f9b63b4ab7114ee60df3526
https://cronfa.swan.ac.uk/Record/cronfa37736/Download/0037736-09022018100623.pdf
https://cronfa.swan.ac.uk/Record/cronfa37736/Download/0037736-09022018100623.pdf
Autor:
Peng Sun, Kevin B. Kim, Howard A. Burris, Omid Hamid, Jeffrey A. Sosman, Jonathan Cebon, Alicia Allred, Peter F. Lebowitz, Gerald S. Falchook, Richard F. Kefford, Karl D. Lewis, Daniele Ouellet, Keith T. Flaherty, J. R. Infante, Lynn M. Schuchter, Adil Daud, Rene Gonzalez, Georgina V. Long, Jeffrey S. Weber, Nageatte Ibrahim, Igor Puzanov, Ragini Kudchadkar, Ajay Singh, Alain Algazi, Shonda M Little, Kiran Patel
Publikováno v:
The New England journal of medicine, vol 367, iss 18
BackgroundResistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a s
Autor:
Yu Shyr, Andrew K. Joe, Kevin B. Kim, Grant A. McArthur, Richard F. Kefford, Richard J. Lee, Antoni Ribas, Stergios J. Moschos, Thomas E. Hutson, Jiang Li, Jeffrey A. Sosman, Donald P. Lawrence, Ravi K. Amaravadi, H. Jeffrey Lawrence, Rene Gonzalez, Anna C. Pavlick, Karl D. Lewis, Jeffrey S. Weber, Lynn M. Schuchter, Fei Ye, Igor Puzanov, Peter Hersey, Keith T. Flaherty, Bartosz Chmielowski, K. B. Nolop
Publikováno v:
New England Journal of Medicine. 366:707-714
Approximately 50% of melanomas harbor activating (V600) mutations in the serine– threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600– mutant metasta
Autor:
Holly Hilton, Nicholas Otte, Julie S. Hang, Ion Niculescu-Duvaz, Felipe C. Geyer, Lidia Robert, K. B. Nolop, Jorge S. Reis-Filho, Luc Andries, Alfonso Zambon, Gideon Bollag, Rene Gonzalez, Natasha Preece, Paul B. Chapman, Damien Kee, Min Jung Kim, Kerstin Trunzer, Dan Niculescu-Duvaz, Stephen Mok, Brian Lestini, Roger S. Lo, Gaston Habets, Amaya Viros, James L. Troy, Caroline J. Springer, Mark M. Kockx, Yan Ma, Igor Puzanov, Carla Milagre, Robert Hayward, Elizabeth A. Burton, Antoni Ribas, Xiangju Kong, Chao Zhang, Matthew J. Martin, Maryou B K Lambros, Andrew K. Joe, Richard C. Koya, Jeffrey A. Sosman, Olivia Spleiss, Johannes Noe, Bartosz Chmielowski, Hoa Nguyen, Richard J. Lee, Keith T. Flaherty, Richard Marais, Nathalie Dhomen, Hong Yang, Bernice Wong, Qiongqing Wang, Grant A. McArthur, Fei Su, Thomas E. Hutson
Publikováno v:
ResearcherID
Cutaneous squamous-cell carcinomas and keratoacanthomas are common findings in patients treated with BRAF inhibitors.We performed a molecular analysis to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and TP53) in the lesions from patients t
Autor:
Jonathan S. Treisman, Phillip D. Leming, Richard L. White, Peter L. Choyke, Donald M. Miller, Kevin C. Conlon, Francesco M. Marincola, David H. Lawson, Timothy M. Kuzel, Eric D. Whitman, Robert M. Conry, Jon M. Richards, Rene Gonzalez, Kari Kendra, Steven A. Rosenberg, Howard L. Kaufman, Douglas S. Reintgen, Fawaz Gailani, Brendan D. Curti, Don Vena, Barbara A. Pockaj, Jai Balkissoon, Maria J. Merino, Patrick Hwu, Douglas J. Schwartzentruber, Lee B. Riley
Publikováno v:
New England Journal of Medicine. 364:2119-2127
Stimulating an immune response against cancer with the use of vaccines remains a challenge. We hypothesized that combining a melanoma vaccine with interleukin-2, an immune activating agent, could improve outcomes. In a previous phase 2 study, patient